Second-line treatment options such as Rituximab (RTX), Azathioprine (AZA), and TPO-RAs like Eltrombopag (ELTRO) or Romiplostim (ROMP) are recommended by the American Society of Hematology guidelines for treating corticosteroid-resistant or intolerant ITP [3,17,19]. Here, TPO is linked to autoimmune thrombocytopenic purpura.